Plasma Transfusions in Children

Introduction to Plasma Transfusions in Children

Plasma transfusions play a crucial role in managing various pediatric conditions associated with coagulation abnormalities. Plasma, the liquid component of blood, contains essential coagulation factors, proteins, and other substances necessary for maintaining hemostasis. Understanding the appropriate use, administration, and potential complications of plasma transfusions is vital for optimal patient care in pediatric settings.

Indications for Plasma Transfusions in Children

Plasma transfusions in children are indicated in several clinical scenarios:

  1. Correction of coagulation factor deficiencies:
    • Multiple factor deficiencies (e.g., liver disease, disseminated intravascular coagulation)
    • Single factor deficiencies when specific factor concentrates are unavailable
    • Vitamin K deficiency (when vitamin K administration is insufficient)
  2. Management of active bleeding:
    • In the presence of prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT)
    • As part of massive transfusion protocols
  3. Reversal of warfarin effect:
    • In cases of warfarin-associated bleeding
    • Prior to urgent invasive procedures in anticoagulated patients
  4. Plasma exchange in specific conditions:
    • Thrombotic thrombocytopenic purpura (TTP)
    • Hemolytic uremic syndrome (HUS)
    • Certain metabolic disorders
  5. Replacement of plasma proteins:
    • Antithrombin III deficiency
    • C1 esterase inhibitor deficiency

It's important to note that plasma should not be used for volume expansion alone, as crystalloids or colloids are more appropriate for this purpose. Additionally, prophylactic use of plasma in non-bleeding patients with mildly abnormal coagulation tests is generally not recommended.

Types of Plasma Products for Pediatric Use

Several types of plasma products are available for transfusion in children:

  1. Fresh Frozen Plasma (FFP):
    • Plasma frozen within 8 hours of collection
    • Contains all coagulation factors, including labile factors V and VIII
    • Stored at -18°C or colder for up to 1 year
  2. Frozen Plasma (FP):
    • Plasma frozen within 24 hours of collection
    • Similar to FFP but with slightly lower levels of factor VIII
    • Used interchangeably with FFP in most clinical situations
  3. Cryoprecipitate-Reduced Plasma:
    • Plasma from which cryoprecipitate has been removed
    • Lower levels of fibrinogen, factor VIII, and von Willebrand factor
    • Used when these factors are not required (e.g., TTP treatment)
  4. Solvent/Detergent-Treated Plasma:
    • Pooled plasma treated to inactivate lipid-enveloped viruses
    • Reduced risk of transfusion-transmitted infections
    • Lower levels of protein S and α2-antiplasmin
  5. Pathogen-Reduced Plasma:
    • Treated with various methods (e.g., amotosalen, riboflavin) to reduce pathogen transmission
    • Maintains adequate levels of most coagulation factors

The choice of plasma product depends on the specific clinical indication, availability, and institutional protocols. In most pediatric cases, FFP or FP are the most commonly used products.

Administration and Dosing of Plasma in Children

Proper administration of plasma transfusions in children requires careful consideration of dosing, infusion rate, and monitoring:

  1. Dosing:
    • Standard dose: 10-15 mL/kg body weight
    • This dose typically raises factor levels by 15-20%
    • Higher doses may be required in severe coagulopathy or ongoing bleeding
  2. ABO compatibility:
    • ABO-identical plasma is preferred
    • If unavailable, ABO-compatible plasma can be used (e.g., AB plasma as universal donor)
  3. Preparation:
    • Thaw frozen plasma at 30-37°C using approved devices
    • Once thawed, store at 1-6°C and use within 24 hours
  4. Infusion rate:
    • Typical rate: 10-20 mL/kg/hour
    • Can be increased in cases of severe bleeding or as part of massive transfusion protocols
    • Monitor for signs of fluid overload, especially in small children or those with cardiac/renal impairment
  5. Monitoring:
    • Assess clinical response (e.g., cessation of bleeding)
    • Monitor coagulation parameters (PT, aPTT, fibrinogen) before and after transfusion
    • Observe for transfusion reactions

It's crucial to reassess the need for ongoing plasma transfusions regularly and to discontinue when the therapeutic goal is achieved or clinical improvement is observed.

Complications and Management of Plasma Transfusions in Children

While plasma transfusions are generally safe, they can be associated with various complications:

  1. Transfusion-Associated Circulatory Overload (TACO):
    • More common in small children or those with cardiac/renal impairment
    • Symptoms: respiratory distress, tachycardia, hypertension
    • Management: slow or stop transfusion, administer diuretics, provide respiratory support
  2. Allergic Reactions:
    • Range from mild urticaria to severe anaphylaxis
    • Management: antihistamines for mild reactions, epinephrine for severe reactions
  3. Transfusion-Related Acute Lung Injury (TRALI):
    • Rare but potentially severe complication
    • Symptoms: acute respiratory distress, hypoxemia, bilateral pulmonary infiltrates
    • Management: supportive care, mechanical ventilation if necessary
  4. Citrate Toxicity:
    • Due to citrate used as anticoagulant in plasma products
    • Can cause hypocalcemia, especially with rapid infusion
    • Management: slow infusion rate, calcium supplementation if symptomatic
  5. Transfusion-Transmitted Infections:
    • Risk is low with current screening practices
    • Includes viruses (e.g., HIV, hepatitis B/C), bacteria, and rarely parasites
  6. Hemolysis:
    • Can occur with ABO-incompatible plasma
    • Prevention: ensure proper ABO compatibility

Prevention and early recognition of these complications are crucial. All transfusions should be closely monitored, and any adverse reactions should be promptly reported and managed.

Special Considerations in Pediatric Plasma Transfusions

Several special considerations apply to plasma transfusions in children:

  1. Neonatal transfusions:
    • Consider smaller aliquots to reduce donor exposure
    • Be aware of increased risk of volume overload and citrate toxicity
    • Use caution in premature infants due to immature hepatic metabolism
  2. Massive transfusion protocols:
    • Include plasma in a fixed ratio with red blood cells and platelets
    • Typically 1:1:1 ratio (RBC:plasma:platelets)
    • May require more frequent monitoring of coagulation parameters
  3. Congenital coagulation factor deficiencies:
    • Specific factor concentrates are preferred when available
    • Plasma may be used if concentrates are unavailable or in emergencies
  4. Patients with IgA deficiency:
    • At risk for anaphylactic reactions to plasma containing IgA
    • Consider using IgA-deficient plasma or washed blood products
  5. Thrombotic Thrombocytopenic Purpura (TTP):
    • Requires large volume plasma exchange
    • Consider cryoprecipitate-reduced or solvent/detergent-treated plasma
  6. Long-term plasma transfusion:
    • May be required in some chronic conditions
    • Monitor for iron overload and consider chelation therapy

These special considerations highlight the importance of individualized approaches to plasma transfusion in pediatric patients, taking into account the specific clinical context, underlying conditions, and potential risks.





Further Reading
Tags:

Powered by Blogger.